Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Pelthos Therapeutics (NYSE American:PTHS) announced that CEO Scott Plesha will present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation is scheduled for 11:05 a.m. ET on June 4, 2026, followed by one-on-one investor meetings arranged through Jefferies representatives.
Positive
- None.
Negative
- None.
News Market Reaction – PTHS
In the May 29 session, PTHS gained 2.60%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 2026 earnings | Positive | +6.5% | Reported growing ZELSUVMI revenue and narrowed net loss versus prior quarter. |
| May 01 | Earnings date notice | Neutral | +0.0% | Announced timing and access details for upcoming Q1 2026 results call. |
| Apr 14 | Conference participation | Neutral | +0.0% | CEO scheduled for one-on-one investor meetings at Piper Sandler symposium. |
| Apr 10 | CFO transition | Neutral | +1.9% | Appointed new CFO with extensive public company finance experience. |
| Mar 31 | Clinical trial start | Positive | +0.1% | First patient dosed in Phase 1b/2a trial of CT2000 for eye pain. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news and earnings have generally aligned with modestly positive or flat price reactions.
Over recent months, Pelthos has reported growing ZELSUVMI revenues, initiated a Phase 1b/2a trial for CT2000, and executed management and governance changes, including a CFO transition. Earnings on May 14 saw a 6.46% gain, while prior conference participation and clinical milestones produced flat to slightly positive reactions. Today’s Jefferies conference participation fits a pattern of routine investor-relations events layered onto an emerging commercial and clinical story.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative.
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel,
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072
